Your browser is no longer supported. Please, upgrade your browser.
RIGL Rigel Pharmaceuticals, Inc. weekly Stock Chart
RIGL [NASD]
Rigel Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.35 Insider Own0.25% Shs Outstand167.19M Perf Week1.20%
Market Cap280.88M Forward P/E- EPS next Y-0.37 Insider Trans13.41% Shs Float167.14M Perf Month-0.59%
Income-58.70M PEG- EPS next Q-0.13 Inst Own93.90% Short Float6.96% Perf Quarter-30.29%
Sales65.80M P/S4.27 EPS this Y28.90% Inst Trans-0.67% Short Ratio8.33 Perf Half Y-28.51%
Book/sh0.47 P/B3.57 EPS next Y-32.10% ROA-39.70% Target Price8.14 Perf Year-44.92%
Cash/sh0.67 P/C2.50 EPS next 5Y- ROE-60.70% 52W Range1.56 - 3.29 Perf YTD-26.96%
Dividend- P/FCF- EPS past 5Y15.50% ROI-66.10% 52W High-48.96% Beta1.35
Dividend %- Quick Ratio4.30 Sales past 5Y44.20% Gross Margin99.00% 52W Low7.69% ATR0.10
Employees160 Current Ratio4.40 Sales Q/Q477.80% Oper. Margin-93.50% RSI (14)47.47 Volatility5.50% 6.04%
OptionableYes Debt/Eq0.00 EPS Q/Q22.10% Profit Margin-89.30% Rel Volume0.66 Prev Close1.63
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume1.40M Price1.68
Recom- SMA20-1.06% SMA50-4.88% SMA200-22.34% Volume923,856 Change2.75%
Sep-26-19Resumed JP Morgan Overweight $7
Mar-01-19Reiterated Cantor Fitzgerald Overweight $9 → $7
Aug-27-18Initiated Citigroup Buy $8.50
May-02-18Reiterated Cantor Fitzgerald Overweight $6 → $9
Dec-21-17Resumed Piper Jaffray Overweight $6
Dec-15-17Initiated Cantor Fitzgerald Overweight $6
Nov-06-17Resumed H.C. Wainwright Buy $7
Mar-09-17Reiterated H.C. Wainwright Buy $6 → $5
Aug-31-16Reiterated H.C. Wainwright Buy $6 → $7
Aug-30-16Reiterated Piper Jaffray Overweight $10 → $11
Jul-13-16Initiated H.C. Wainwright Buy $6
Jun-13-16Initiated Piper Jaffray Overweight
Apr-22-16Upgrade JP Morgan Neutral → Overweight
Apr-08-13Reiterated Stifel Buy $11 → $7
Nov-29-12Initiated UBS Neutral $9
Nov-06-12Reiterated Oppenheimer Outperform $12 → $15
Mar-26-12Initiated Canaccord Genuity Hold $8
Dec-10-10Downgrade MP Advisors Outperform → Market Perform
Mar-12-10Initiated Piper Jaffray Overweight
Nov-23-09Upgrade RBC Capital Mkts Sector Perform → Outperform
Oct-18-19 07:30AM  Rigel Receives Positive Trend Vote from CHMP for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe PR Newswire
Oct-16-19 07:30AM  Rigel to Host Investor and Analyst Call on October 23, 2019 PR Newswire
Oct-14-19 10:28AM  Aclaris Divests Rhofade to EPI Health for $55M, Shares Up Zacks
Oct-02-19 07:00AM  Rigel Secures Credit Facility for Up to $60 Million PR Newswire
Sep-23-19 07:30AM  Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia PR Newswire
Sep-20-19 01:33PM  Should You Be Concerned About Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Historical Volatility? Simply Wall St.
Sep-15-19 03:28PM  Stocks That Fell to 3-Year Lows in the Week of Sept. 13 GuruFocus.com
Aug-28-19 07:30AM  Rigel's CEO to Participate in Panel Discussion at Citi's 14th Annual Biotech Conference PR Newswire
Aug-16-19 11:26AM  Who Has Been Buying Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares? Simply Wall St.
Aug-10-19 12:04AM  Edited Transcript of RIGL earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-06-19 09:24PM  Rigel Pharmaceuticals Inc (RIGL) Q2 2019 Earnings Call Transcript Motley Fool
06:25PM  Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM  Rigel Announces Second Quarter 2019 Financial Results and Provides Business Update PR Newswire
Aug-02-19 09:06AM  What's in the Cards for Bausch Health (BHC) in Q2 Earnings? Zacks -5.70%
08:44AM  Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings? Zacks
Jul-30-19 07:30AM  Rigel Announces Conference Call and Webcast to Report Second Quarter 2019 Financial Results PR Newswire
Jul-09-19 07:56AM  Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): Are Analysts Optimistic? Simply Wall St.
Jul-01-19 07:15AM  Rigel Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Jun-27-19 09:50AM  Dova Receives Approval for Doptelet in Europe, Stock Up Zacks
Jun-23-19 08:54PM  Heres What Hedge Funds Think About Rigel Pharmaceuticals, Inc. (RIGL) Insider Monkey
Jun-13-19 07:30AM  Rigel to Present Two Posters Highlighting Fostamatinib at the 24 Congress of the European Hematology Association (EHA) PR Newswire
Jun-12-19 08:15AM  Is Rigel Pharmaceuticals a Buy? Motley Fool
Jun-05-19 06:42AM  Rigel Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Jun-03-19 02:38PM  Edited Transcript of RIGL earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-31-19 07:30AM  Rigel to Present at Jefferies 2019 Healthcare Conference PR Newswire
May-17-19 09:05AM  Rigel Initiates Enrollment in Pivotal Blood Disorder Study Zacks
May-16-19 07:30AM  Rigel Enrolls First Patient in Phase 3 Clinical Trial of Fostamatinib Disodium Hexahydrate in Warm Autoimmune Hemolytic Anemia PR Newswire
May-08-19 12:23AM  Rigel Pharmaceuticals Inc (RIGL) Q1 2019 Earnings Call Transcript Motley Fool
May-07-19 06:05PM  Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates Zacks
05:03PM  Rigel: 1Q Earnings Snapshot Associated Press
04:01PM  Rigel Announces First Quarter 2019 Financial Results and Provides Company Update PR Newswire
Apr-30-19 07:30AM  Rigel Announces Conference Call and Webcast to Report First Quarter 2019 Financial Results and Company Update PR Newswire
Apr-17-19 03:53PM  If You Had Bought Rigel Pharmaceuticals (NASDAQ:RIGL) Stock A Year Ago, You'd Be Sitting On A 40% Loss, Today Simply Wall St. -6.45%
Apr-09-19 08:29PM  Here's Why Rigel Pharmaceuticals Gained 17.3% in March Motley Fool
Mar-26-19 07:30AM  Rigel Welcomes Jane Wasman to Board of Directors PR Newswire
Mar-12-19 12:17PM  Is Rigel Pharmaceuticals, Inc.s (NASDAQ:RIGL) CEO Overpaid Relative To Its Peers? Simply Wall St.
Mar-06-19 12:32AM  Edited Transcript of RIGL earnings conference call or presentation 28-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
Mar-01-19 09:18AM  Rigel Pharmaceuticals (RIGL) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-28-19 04:01PM  Rigel Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update PR Newswire
Feb-21-19 07:30AM  Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End Financial Results PR Newswire
Jan-26-19 11:34AM  Is Rigel Pharmaceuticals a Buy? Motley Fool
Jan-24-19 07:35AM  Market Trends Toward New Normal in SeaWorld Entertainment, Rigel Pharmaceuticals, Guidewire Software, Editas Medicine, Jones Energy, and Rexahn Pharmaceuticals Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jan-23-19 10:20AM  Rigel Rises On European Marketing Agreement For Autoimmune Drug Benzinga
09:45AM  4 Healthcare Stocks Making Moves On Wednesday (1/23/19) ACCESSWIRE
07:51AM  Rigel Pharmaceuticals stock up 9% after announcing licensing agreement with Grifols MarketWatch
07:30AM  Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe PR Newswire
Jan-15-19 02:33PM  Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): When Will It Breakeven? Simply Wall St.
Jan-07-19 07:30AM  Rigel Pharmaceuticals Provides Business Update PR Newswire +5.08%
Jan-03-19 04:30PM  Rigel to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire -8.05%
Dec-19-18 12:38AM  Rigel Pharmaceuticals, Inc. (RIGL): Hedge Fund Sentiment Unchanged Insider Monkey
Dec-18-18 08:55AM  Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved Benzinga
Dec-05-18 07:30AM  Rigel to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York City PR Newswire
Dec-03-18 07:45AM  New Research Coverage Highlights Weight Watchers International, Rudolph Technologies, Lowe's Companies, Net 1 UEPS Technologies, Viasat, and Rigel Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire +8.83%
Nov-29-18 01:41PM  What does Rigel Pharmaceuticals Incs (NASDAQ:RIGL) Balance Sheet Tell Us About Its Future? Simply Wall St.
Nov-19-18 08:31AM  Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options Zacks -6.64%
Nov-06-18 11:25PM  Edited Transcript of RIGL earnings conference call or presentation 6-Nov-18 10:00pm GMT Thomson Reuters StreetEvents
05:55PM  Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:51PM  Rigel: 3Q Earnings Snapshot Associated Press
04:01PM  Rigel Announces Third Quarter 2018 Financial Results and Provides Company Update PR Newswire
Nov-01-18 04:01PM  Rigel to Present Data on Fostamatinib in Three Presentations at the 60th American Society of Hematology Annual Meeting & Exposition PR Newswire
Oct-30-18 07:30AM  Rigel Announces Conference Call and Webcast to Report Third Quarter 2018 Financial Results PR Newswire
Oct-29-18 08:00AM  Rigel Pharmaceuticals Enters Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. to Develop and Commercialize TAVALISSE (fostamatinib disodium hexahydrate) in Japan and other Asian Countries PR Newswire
Oct-24-18 09:20AM  Analysis: Positioning to Benefit within Spectrum Pharmaceuticals, Carnival, Cadence Design, Tandem Diabetes Care, Rigel Pharmaceuticals, and Regeneron Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire -5.54%
Oct-15-18 02:05PM  How Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Can Impact Your Portfolio Volatility Simply Wall St.
Oct-12-18 10:29AM  Rigel (RIGL) Gets EMA Acceptance for Thrombocytopenia Drug Zacks
Oct-11-18 07:30AM  Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients PR Newswire
Sep-27-18 07:30AM  Rigel to Host Investor & Analyst Day in New York City on October 4, 2018 PR Newswire
Sep-24-18 07:30AM  Rigel to Present at the Cantor Global Healthcare Conference PR Newswire
Sep-18-18 08:30AM  Rigel Pharmaceuticals (RIGL) in Focus: Stock Moves 6.2% Higher Zacks
Sep-10-18 09:03PM  Here's Why Rigel Pharmaceuticals, Inc. Jumped Over 20% in August Motley Fool
Aug-31-18 08:25AM  New Research Coverage Highlights Argos Therapeutics, Triumph Group, Rigel Pharmaceuticals, Egalet, Hertz Global, and ACADIA Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Aug-30-18 08:00AM  Rigel Pharmaceuticals, Traction from TAVALISSE(TM) Sales and Pipeline, Analysts Review and Target ACCESSWIRE
Aug-29-18 07:30AM  Rigel to Present at the 20th Annual Global Investment Conference in New York City PR Newswire
Aug-24-18 01:50AM  Edited Transcript of RIGL earnings conference call or presentation 8-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
Aug-09-18 12:59PM  Here's Why Rigel Pharmaceuticals, Inc. Rose as Much as 17.2% Today Motley Fool +12.69%
Aug-08-18 06:20PM  Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:18PM  Rigel: 2Q Earnings Snapshot Associated Press
04:07PM  Rigel Announces Second Quarter 2018 Financial Results and Provides Company Update PR Newswire
03:00PM  Rigel Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 07:30AM  Rigel Announces Conference Call and Webcast to Report Second Quarter 2018 Financial Results PR Newswire
Jul-31-18 07:00AM  Free Technical Reports on Sarepta Therapeutics and Three Additional Biotech Equities ACCESSWIRE
Jul-27-18 09:48AM  10 Strong Buy Stocks for Under $10 Kiplinger
07:35AM  Recent Analysis Shows Synopsys, Rigel Pharmaceuticals, Fate Therapeutics, Philip Morris International, Sally Beauty, and Kimberly-Clark Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jun-26-18 07:30AM  Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases PR Newswire
Jun-20-18 04:01PM  Rigel Announces Poster Presentations at FOCIS Annual Meeting PR Newswire
Jun-18-18 08:15AM  Rigel Pharmaceuticals Wins FDA Approval, Potential Clinical Catalysts and Analyst Review ACCESSWIRE
Jun-12-18 07:30AM  Rigel To Present Phase 2 Results for Fostamatinib in Autoimmune Hemolytic Anemia at EHA PR Newswire
May-31-18 07:30AM  Rigel to Present at Jefferies 2018 Global Healthcare Conference PR Newswire
May-30-18 08:14AM  Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA Benzinga -9.78%
07:30AM  Rigel Appoints Dean Schorno as Chief Financial Officer PR Newswire
May-29-18 07:30AM  Rigel Announces Availability of TAVALISSE (fostamatinib disodium hexahydrate) in the U.S. PR Newswire -5.88%
May-09-18 03:59AM  Edited Transcript of RIGL earnings conference call or presentation 1-May-18 9:00pm GMT Thomson Reuters StreetEvents
May-02-18 07:41AM  Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings Benzinga
May-01-18 04:58PM  Rigel: 1Q Earnings Snapshot Associated Press
04:01PM  Rigel Announces First Quarter 2018 Financial Results and Provides Company Update PR Newswire
Apr-30-18 07:30AM  TAVALISSE (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo PR Newswire
Apr-19-18 07:31PM  Rigel Announces Pricing Of Public Offering Of Common Stock PR Newswire
04:31PM  Why Bank of New York Mellon, Snap-on, and Rigel Pharmaceuticals Jumped Today Motley Fool
Apr-18-18 04:34PM  Rigel Announces Proposed Public Offering Of Common Stock PR Newswire -5.60%
01:23PM  Analysts See 100% Upside To Rigel After Tavalisse Approval Benzinga
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia. Its clinical programs also comprise R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) program, which is in Phase I clinical study for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is based in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schorno Dean LEVP &Chief Financial OfficerMay 22Buy2.1350,000106,54450,000May 23 08:21 PM